Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT00568815
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
31
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma
Interventions
DRUG:
Rituximab combined with ESHAP
Sponsor
Fudan University